Varda Space Industries, a microgravity-enabled life sciences company based in El Segundo, California, has closed a Series D funding round of US$251 million. The round was led by Lux Capital and Natural Capital, with participation from Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step, and Also Capital. This latest investment brings total capital raised to US$598 million and supports the goal of producing the first pharmaceuticals made in space for patients on Earth.
Building Toward the First Medicine Made in Space
Varda is focused on using microgravity to crystallize active pharmaceutical ingredients in ways that cannot be achieved on Earth. The absence of gravity enables novel drug formulations with potential benefits for patients, including improved solubility and delivery. The company says the first product manufactured in space and consumed on Earth will be a pharmaceutical.
Decades of International Space Station research have demonstrated the potential of microgravity for drug formulation. Varda states that it is now the only company with the launch cadence, reentry capability, and pharmaceutical science team needed to bring that potential to market. The company is transforming in-space pharmaceutical processing into a reliable part of the drug development pipeline.
A Record of Launches and Reentries
Since its first mission launched in 2023, Varda has completed six successful reentry missions. The company has more than a dozen additional launches and reentries planned through 2028. Its W-Series vehicles, which reach Mach 25 on reentry from orbit, provide government and commercial partners with a repeatable way to return materials and data from space to Earth.
Lux Capital Partner Shahin Farshchi said, "In-space manufacturing means building what space needs, in space, and making what Earth can't." He added that Varda is the first and only company delivering a real cadence of launches and reentries, with capsules built to manufacture the impossible and return it home. The statement reflects investor confidence in the company's ability to make drugs that cannot be produced under gravity.
Capital to Accelerate Pharmaceutical Partnerships
Varda co-founder and President Delian Asparouhov said, "We started Varda with the conviction that the first product manufactured in space and consumed on Earth would be a pharmaceutical." He added that this round gives the company resources to increase cadence, deepen pharmaceutical partnerships, and get closer to delivering the first medicine made in space. The funding also supports the company's effort to make in-space manufacturing a normal, reliable part of the drug development pipeline.
As launch cadence across the industry continues to increase, Varda argues that the ability to bring things back will become as foundational as the ability to send them up. The company's reentry capability positions it to serve both pharmaceutical production and broader commercial or government needs. The new funding is expected to scale these operations, support future missions, and strengthen Varda's role in the space economy.
Investor Confidence in Space-Based Drug Manufacturing
The Series D round attracted a combination of new and existing investors with backgrounds in deep technology and life sciences. Their participation signals growing confidence in the commercial market for microgravity-enabled pharmaceutical processing. The capital will support Varda's efforts to move from successful flight demonstrations toward regulated pharmaceutical production and expanded partnership agreements.
Varda Space Industries has positioned itself at the intersection of space infrastructure and life sciences with a clear focus on pharmaceutical manufacturing. The US$251 million Series D round, which brings total funding to US$598 million, provides capital to expand flight cadence and advance drug development partnerships. As the company moves toward producing the first medicine made in space for use on Earth, it aims to make microgravity a practical tool for the pharmaceutical industry.